retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Retatrutide's mechanisms of action Retatrutide just had its biggest

Study type: off-treatment extension of a randomized trial

Future research should address these limitations by including a more comprehensive range of studies, providing detailed GLP-1RAs classification information, and reporting precise dosages used in the treatment protocols

This has obvious benefits for those with Type 2 diabetes, but it can also help those who struggle with insulin resistance and weight maintenance

More research is needed to verify the effects genetic variations can have on weight loss with GLP-1s

Clinical trials have demonstrated varying efficacy across the class, with weight reductions ranging from approximately 5-8% with liraglutide 3 mg to 15% with semaglutide 2.4 mg and 10-22% with tirzepatide, depending on dose